Retatrutide
Retatrutide • Also called RETA
Retatrutide is one of the highest-interest metabolic peptides online, but FDA has explicitly said it is not eligible for use in compounding under section 503A.
Current status
Restricted
Weight-management and metabolic interest, with current federal compounding constraints still in play.
FDA category
Not on 503A bulks list
Can pharmacies compound this?
No
Reclassification expected?
Unclear
Market demand is strong, but that has not changed the federal compounding posture. FDA's concern here is direct and current.
Primary Use
Weight-management and metabolic interest
Also searched as
RETA
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Dec 8, 2025
Current status signal recorded: FDA warning-letter posture says retatrutide is not identified as an active ingredient in any FDA-approved drug and is not eligible for 503A compounding..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Retatrutide status changes
State-specific notes
Florida
Consumer demand is high, but lawful compounding support is still not there.